Spotlight Innovation Inc., a pharmaceutical company, acquires and develops proprietary therapies to address unmet medical needs with an emphasis on rare, emerging, and neglected diseases. It identifies in-licensing opportunities and manages product development through partnerships with universities, medical schools, contract research organizations, and contract manufacturing organizations, as well as pursues product commercialization opportunities, including out-licensing and strategic partnerships. The company is developing Crotoxin, which is in Phase I clinical study for the treatment of cancer. It also develops various compounds for the treatment of viral infections, including Zika virus infection; and products derived from cobra venom to treat chronic pain. Spotlight Innovation Inc. has a license agreement with Indiana University Research and Technology Corporation to commercialize STL-182, an orally-available small molecule that might have therapeutic potential for treating spinal muscular atrophy. The company is based in Urbandale, Iowa.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone515-274-9087
Debt
Price-To-Earnings
Sales & Book Value
Annual SalesN/A
Profitability
Miscellaneous
Employees4
Next Earnings DateN/A
OptionableNot Optionable
Spotlight Innovation (OTCMKTS:STLT) Frequently Asked Questions
What is Spotlight Innovation's stock symbol?
Spotlight Innovation trades on the OTCMKTS under the ticker symbol "STLT."
Has Spotlight Innovation been receiving favorable news coverage?
News stories about STLT stock have trended somewhat positive recently, according to InfoTrie Sentiment. The research firm scores the sentiment of media coverage by analyzing more than six thousand news and blog sources in real-time. The firm ranks coverage of companies on a scale of -5 to 5, with scores closest to five being the most favorable. Spotlight Innovation earned a news sentiment score of 1.3 on InfoTrie's scale. They also assigned media stories about the company a news buzz of 10.0 out of 10, meaning that recent media coverage is extremely likely to have an impact on the stock's share price in the next few days. View News Stories for Spotlight Innovation.
Who are some of Spotlight Innovation's key competitors?
Some companies that are related to Spotlight Innovation include Anthera Pharmaceuticals (ANTH), Cotinga Pharmaceuticals (COTQF), Peak Pharmaceuticals (PKPH), Capstone Therapeutics (CAPS), Achaogen (AKAOQ), Argos Therapeutics (ARGSQ), Respirerx Pharmaceuticals (RSPI), HST Global (HSTC), Propanc Biopharma (PPCB), Targeted Medical Pharma (TRGM), Skinvisible (SKVI), Orexigen Therapeutics (OREXQ), Inspyr Therapeutics (NSPX), Immune Therapeutics (IMUN) and 89bio (ETNB).
What other stocks do shareholders of Spotlight Innovation own?
Who are Spotlight Innovation's key executives?
Spotlight Innovation's management team includes the folowing people:
- Mr. John Michael Krohn, Chairman, CEO, Pres, COO & Interim CFO (Age 60)
- Mr. Cristopher Grunewald, Consultant (Age 46)
- Mr. Rene Erickson, VP of Corp. Communications
- Dr. Geoffrey M. Laff Ph.D., Sr. VP of Bus. Devel.
How do I buy shares of Spotlight Innovation?
Shares of STLT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is Spotlight Innovation's stock price today?
One share of STLT stock can currently be purchased for approximately $0.01.
How big of a company is Spotlight Innovation?
What is Spotlight Innovation's official website?
How can I contact Spotlight Innovation?
Spotlight Innovation's mailing address is 11147 AURORA AVENUE AURORA BUSINESS PARK BUILDING 3, URBANDALE IA, 50322. The company can be reached via phone at 515-274-9087 or via email at [email protected]
MarketBeat Community Rating for Spotlight Innovation (OTCMKTS STLT)
MarketBeat's community ratings are surveys of what our community members think about Spotlight Innovation and other stocks. Vote "Outperform" if you believe STLT will outperform the S&P 500 over the long term. Vote "Underperform" if you believe STLT will underperform the S&P 500 over the long term. You may vote once every thirty days.
